Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus using a Delphi process.
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
Eleven evidence-based recommendations for the non-pharmacological core management of hip and knee OA were developed, concerning the following nine topics: assessment, general approach, patient information and education, lifestyle changes, exercise, weight loss, assistive technology and adaptations, footwear and work.
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology
Recommendations on glucocorticoid treatment are presented that reflect current and best knowledge available and take into account current clinical practice.
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
- J. D. da Silva, J. Jacobs, J. Bijlsma
- Medicine, BiologyAnnals of the rheumatic diseases
- 17 August 2005
Safety data from recent randomised controlled clinical trials of low dose glucocorticoid treatment in RA suggest that adverse effects associated with this drug are modest, and often not statistically different from those of placebo.
Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus.
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.
It is the opinion of the EULAR executive committee members that “guidelines” might appear too constraining and that, on the other hand, “points to consider’ might be considered as too open.
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
Nine final recommendations for the management of medium to high-dose systemic GC therapy in rheumatic diseases were selected and evaluated with their strengths of recommendations.
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus.